Last reviewed · How we verify
Madrilenian Group of Cutaneous Lymphomas — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| PUVA (8MOP + UVA) + IFN | PUVA (8MOP + UVA) + IFN | marketed | Photochemotherapy + cytokine combination | Oncology | ||
| PUVA (8-MOP + UVA) | PUVA (8-MOP + UVA) | marketed | Photochemotherapy agent | DNA (non-specific cross-linking) | Oncology |
Therapeutic area mix
- Oncology · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- M.D. Anderson Cancer Center · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Madrilenian Group of Cutaneous Lymphomas:
- Madrilenian Group of Cutaneous Lymphomas pipeline updates — RSS
- Madrilenian Group of Cutaneous Lymphomas pipeline updates — Atom
- Madrilenian Group of Cutaneous Lymphomas pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Madrilenian Group of Cutaneous Lymphomas — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/madrilenian-group-of-cutaneous-lymphomas. Accessed 2026-05-17.